Several agents are in clinical trials: sarilumab, olokizumab (CDP6038) elsilimomab, ALD518/BMS-945429, sirukumab (CNTO 136), and CPSI-2364 an apparent macrophage-specific inhibitor of the p38 mitogen-activated protein kinase pathway.
New research has found IL-6 to be an anti-inflammatory cytokine with multiple beneficial effects when released by contracting muscle as a myokine. IL-6 had previously been classified as a proinflammatory cytokine. Therefore, it was first thought that the exercise-induced IL-6 response was related to muscle damage. However, it has become evident that eccentric exercises are not associated with a larger increase in plasma IL-6 than exercise involving concentric “nondamaging” muscle contractions. This finding demonstrates that muscle damage is not required to provoke an increase in plasma IL-6 during exercise. In fact, eccentric exercise may result in a delayed peak and a much slower decrease of plasma IL-6 during recovery.
Anti-IL-6 therapies should therefore take into consideration the (beneficial) anti-inflammatory effects of myokines generally, including the now-established multiple benefits of muscle-derived Interleukin 6.
Food and diet
- Jones SA, Scheller J, Rose-John S (2011). "Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling". J. Clin. Invest. 121 (9): 3375–83. doi:10.1172/JCI57158. PMC 3163962. PMID 21881215.
- Barton BE (August 2005). "Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes". Expert Opin. Ther. Targets 9 (4): 737–52. doi:10.1517/1472822.214.171.1247. PMID 16083340.
- Smolen JS, Maini RN (2006). "Interleukin-6: a new therapeutic target". Arthritis Res. Ther. 8 Suppl 2: S5. doi:10.1186/ar1969. PMC 3226077. PMID 16899109.
- Stein and Sutherland (1998). "IL-6 as a drug discovery target". Drug Discovery Today 3 (5): 202–213. doi:10.1016/S1359-6446(97)01164-1.
- "Interleukin-6 - new target in the battle against Ras-induced cancers". 2007.
- "Interleukin 6 as a therapeutic target in systemic-onset juvenile idiopathic arthritis". 2003.
- Schoels MM, van der Heijde D, Breedveld FC et al. (2013). "Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement". Ann. Rheum. Dis. 72 (4): 583–9. doi:10.1136/annrheumdis-2012-202470. PMC 3595140. PMID 23144446.
- "UCB Announces Start Of Phase I Study For Antibody Drug Candidate CDP6038". 2 Dec 2008.
- PMID: 23598944
- "ArGEN-X Wins €1.5M IWT Grant to Progress Camelid-Derived Human Antibody Pipeline". 27 Sep 2010.
- "Formatech to Donate Services to Formulate and Fill Femta Pharmaceuticals’ FM101 Monoclonal Antibody under Its "Fillanthrop". 30 July 2010.
- Bruunsgaard H, Galbo H, Halkjaer-Kristensen J, Johansen TL, MacLean DA, Pedersen BK. Exercise-induced increase in interleukin-6 is related to muscle damage. J Physiol Lond 499: 833-841, 1997.
- Muscle as a secretory organ. Pedersen BK. American Physiological Society. Compr Physiol 3:1337-1362, 2013. http://www.inflammation-metabolism.dk/index.php?pageid=21&pmid=23897689
- Muscle as a secretory organ. Pedersen BK Compr Physiol 2013; 3(3): 1337-62 http://www.inflammation-metabolism.dk/index.php?pageid=21&pmid=23897689
- Johnson; Kelley, KW; Johnson, RW et al. (May 2008). "Luteolin reduces IL-6 production in microglia by inhibiting JNK phosphorylation and activation of AP-1 — PNAS". Proceedings of the National Academy of Sciences of the United States of America 105 (21): 7534–9. doi:10.1073/pnas.0802865105. PMC 2396685. PMID 18490655.
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|